Drugdiscovery >> Drugs >> News
4589
Views
Rituxan and Arzerra get a boxed warning of HBV risk - drugdiscovery.com
Rituxan and Arzerra get a boxed warning of HBV risk - drugdiscovery.com


The anti-CD20-directed monoclonal antibodies used to treat chronic lymphocytic leukemia, rituximab (Rituxan) and ofatumumab (Arzerra), will from now carry a boxed warning of the risk for immunosuppression-related reactivation of hepatitis B virus (HBV), the FDA announced.
Read More >>


Tags: Rituxan, Arzerra, warning, HBV, risk - September 26, 2013
Related Articles
4161
Views
Rituxan: indications, interactions, side effects and warnings Rituxan: indications, interactions, side effects and warnings
Rituxan (rituximab) is a monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. It is used to treat diseases which are characterized by excessi Read More >>

Tags: Rituxan, rituximab, CD20, monoclonal antibody

3012
Views
Rituxan and Benlysta rated high in EU5 Rituxan and Benlysta rated high in EU5
Rheumatologists in the EU5 countries (France, Germany, Italy, Spain, United Kingdom) give Rituxan and Benlysta the highest satisfaction and overall product performance ratings for the treatment of mo Read More >>

Tags: rituxan, benlysta, systemic lupus erythematosus, lupus, ratings, EU5

5539
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

3314
Views
Plavix Warning Plavix Warning
Latest research shows that prolonged use (for more than a year) of a blood thinner Plavix by patients after they have received artery-opening stents can lead to fatal bleeding. A consumer advocacy gro Read More >>

Tags: plavix, blood thinner, prolonged use, artery-opening stents, stent, risk, bleeding

3629
Views
Death warning for Pfizer's antibiotic Tygacil Death warning for Pfizer's antibiotic Tygacil
The intravenous antibiotic Tygacil (tigecycline) is approved as a treatment for complicated skin and skin structure infections and community-acquired bacterial pneumonia. The FDA decided to add a boxe Read More >>

Tags: Tygacil, tigecycline, antibiotic, death warning, warning, FDA, label, Pfizer

3549
Views
New Therapy  for ANCA-associated Vasculitis? New Therapy for ANCA-associated Vasculitis?
Researchers demonstrated that rituximab is as effective as cyclophosphamide - the current standard of care in patients with ANCA-associated Vasculitis, but has a shorter and simpler treatment course a Read More >>

Tags: ANCA-associated Vasculitis, Rituximab, Rituxan

3690
Views
Red warning soon on Tylenol Red warning soon on Tylenol
Johnson & Johnson will add red warning on the cap of each new bottle of Extra Strength Tylenol sold in the U.S. The aim is to alert users of potentially fatal risks of taking too much of this pain rel Read More >>

Tags: Johnson & Johnson, Tylenol, tylenol, risks, pain reliever, acetaminophen, liver failure

4945
Views
Celgene’s cancer drug Imnovid may cause birth defects Celgene’s cancer drug Imnovid may cause birth defects
Imnovid (pomalidomide) has recently been approved in Europe for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Recent observations in animal models suggest that th Read More >>

Tags: imnovid, pomalidomide, teratogenic effect, multiple myeloma, warning, birth defects

3422
Views
The FDA warns about Ortiga supplement The FDA warns about Ortiga supplement
Ortiga is unapproved product promoted for a range of health conditions and sold on multiple websites. FDA analysis confirmed that Ortiga contains diclofenac, a prescription non-steroidal anti-inflamma Read More >>

Tags: ortiga, ortiga supplement, FDA warning, diclofenac, non-steroidal anti-inflammatory

6955
Views
Nizoral (ketoconazole) warning Nizoral (ketoconazole) warning
FDA has limited Nizoral oral tablets use due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Read More >>

Tags: Nizoral, ketoconazole, liver injury, drug interactions, drug safety, adrenal gland problems

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013